Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Gene therapy for primary immunodeficiencies: current status and future prospects.
[wiskott-aldrich syndrome]
Gene
therapy
using
autologous
haematopoietic
stem
cells
offers
a
valuable
treatment
option
for
patients
with
primary
immunodeficiencies
who
do
not
have
access
to
an
HLA-matched
donor
,
although
such
treatments
have
not
been
without
their
problems
.
This
review
details
gene
therapy
trials
for
X-
linked
and
adenosine
deaminase
(
ADA
)
-
deficient
severe
combined
immunodeficiency
(
SCID
)
,
Wiskott-
Aldrich
syndrome
(
WAS
)
and
chronic
granulomatous
disease
(
CGD
)
.
X-
linked
SCID
was
chosen
for
gene
therapy
because
of
previous
'
natural
'
genetic
correction
through
a
reversion
event
in
a
single
lymphoid
precursor
,
demonstrating
limited
thymopoiesis
and
restricted
T
-
lymphocyte
receptor
repertoire
,
showing
selective
advantage
of
progenitors
possessing
the
wild-
type
gene
.
In
early
studies
,
patients
were
treated
with
long
terminal
repeats-intact
gamma-retroviral
vectors
,
without
additional
chemotherapy
.
Early
results
demonstrated
gene
-transduced
cells
,
sustained
thymopoiesis
,
and
a
diverse
T
-
lymphocyte
repertoire
with
normal
function
.
Serious
adverse
effects
were
subsequently
reported
in
5
of
20
patients
,
with
T
-
lymphocyte
leukaemia
developing
,
secondary
to
the
viral
vector
integrating
adjacent
to
a
known
oncogene
.
New
trials
using
self-inactivating
gamma-retroviral
vectors
are
progressing
.
Trials
for
ADA
-
SCID
using
gamma-retroviral
vectors
have
been
successful
,
with
no
similar
serious
adverse
effects
reported
;
trials
using
lentiviral
vectors
are
in
progress
.
Patients
with
WAS
and
CGD
treated
with
early
gamma-retroviral
vectors
have
developed
similar
lymphoproliferative
adverse
effects
to
those
seen
in
X-
SCID
--current
trials
are
using
new-generation
vectors
.
Targeted
gene
insertion
using
homologous
recombination
of
corrected
gene
sequences
by
cellular
DNA
repair
pathways
following
targeted
DNA
breakage
will
improve
efficacy
and
safety
of
gene
therapy
.
A
number
of
new
techniques
are
discussed
.
Diseases
Validation
Diseases presenting
"patients were treated with long terminal repeats-intact gamma-retroviral vectors"
symptom
severe combined immunodeficiency
wiskott-aldrich syndrome
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom